173 related articles for article (PubMed ID: 21573016)
1. FANCD1/BRCA2 plays predominant role in the repair of DNA damage induced by ACNU or TMZ.
Kondo N; Takahashi A; Mori E; Noda T; Zdzienicka MZ; Thompson LH; Helleday T; Suzuki M; Kinashi Y; Masunaga S; Ono K; Hasegawa M; Ohnishi T
PLoS One; 2011 May; 6(5):e19659. PubMed ID: 21573016
[TBL] [Abstract][Full Text] [Related]
2. Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1.
Hussain S; Witt E; Huber PA; Medhurst AL; Ashworth A; Mathew CG
Hum Mol Genet; 2003 Oct; 12(19):2503-10. PubMed ID: 12915460
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma.
Wang Y; Chen X; Zhang Z; Li S; Chen B; Wu C; Wang L; Zhang X; Wang J; Chen L; Jiang T
Neurosurg Rev; 2014 Jan; 37(1):73-8. PubMed ID: 23912878
[TBL] [Abstract][Full Text] [Related]
4. DNA ligase IV is a potential molecular target in ACNU sensitivity.
Kondo N; Takahashi A; Mori E; Noda T; Su X; Ohnishi K; McKinnon PJ; Sakaki T; Nakase H; Ono K; Ohnishi T
Cancer Sci; 2010 Aug; 101(8):1881-5. PubMed ID: 20487264
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM.
Tomicic MT; Meise R; Aasland D; Berte N; Kitzinger R; Krämer OH; Kaina B; Christmann M
Oncotarget; 2015 Oct; 6(32):33755-68. PubMed ID: 26418950
[TBL] [Abstract][Full Text] [Related]
6. Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways.
Liu X; Han EK; Anderson M; Shi Y; Semizarov D; Wang G; McGonigal T; Roberts L; Lasko L; Palma J; Zhu GD; Penning T; Rosenberg S; Giranda VL; Luo Y; Leverson J; Johnson EF; Shoemaker AR
Mol Cancer Res; 2009 Oct; 7(10):1686-92. PubMed ID: 19825992
[TBL] [Abstract][Full Text] [Related]
7. Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance.
Yamamuro S; Takahashi M; Satomi K; Sasaki N; Kobayashi T; Uchida E; Kawauchi D; Nakano T; Fujii T; Narita Y; Kondo A; Wada K; Yoshino A; Ichimura K; Tomiyama A
Cancer Sci; 2021 Nov; 112(11):4736-4747. PubMed ID: 34536314
[TBL] [Abstract][Full Text] [Related]
8. Inducibility of nuclear Rad51 foci after DNA damage distinguishes all Fanconi anemia complementation groups from D1/BRCA2.
Godthelp BC; Wiegant WW; Waisfisz Q; Medhurst AL; Arwert F; Joenje H; Zdzienicka MZ
Mutat Res; 2006 Feb; 594(1-2):39-48. PubMed ID: 16154163
[TBL] [Abstract][Full Text] [Related]
9. Tetratricopeptide-motif-mediated interaction of FANCG with recombination proteins XRCC3 and BRCA2.
Hussain S; Wilson JB; Blom E; Thompson LH; Sung P; Gordon SM; Kupfer GM; Joenje H; Mathew CG; Jones NJ
DNA Repair (Amst); 2006 May; 5(5):629-40. PubMed ID: 16621732
[TBL] [Abstract][Full Text] [Related]
10. Fanconi anemia complementation group D2 (FANCD2) functions independently of BRCA2- and RAD51-associated homologous recombination in response to DNA damage.
Ohashi A; Zdzienicka MZ; Chen J; Couch FJ
J Biol Chem; 2005 Apr; 280(15):14877-83. PubMed ID: 15671039
[TBL] [Abstract][Full Text] [Related]
11. Functional interplay between BRCA2/FancD1 and FancC in DNA repair.
Kitao H; Yamamoto K; Matsushita N; Ohzeki M; Ishiai M; Takata M
J Biol Chem; 2006 Jul; 281(30):21312-21320. PubMed ID: 16687415
[TBL] [Abstract][Full Text] [Related]
12. DNA ligase IV as a new molecular target for temozolomide.
Kondo N; Takahashi A; Mori E; Ohnishi K; McKinnon PJ; Sakaki T; Nakase H; Ohnishi T
Biochem Biophys Res Commun; 2009 Oct; 387(4):656-60. PubMed ID: 19615340
[TBL] [Abstract][Full Text] [Related]
13. Distinct roles of BRCA2 in replication fork protection in response to hydroxyurea and DNA interstrand cross-links.
Rickman KA; Noonan RJ; Lach FP; Sridhar S; Wang AT; Abhyankar A; Huang A; Kelly M; Auerbach AD; Smogorzewska A
Genes Dev; 2020 Jun; 34(11-12):832-846. PubMed ID: 32354836
[TBL] [Abstract][Full Text] [Related]
14. Repair pathways independent of the Fanconi anemia nuclear core complex play a predominant role in mitigating formaldehyde-induced DNA damage.
Noda T; Takahashi A; Kondo N; Mori E; Okamoto N; Nakagawa Y; Ohnishi K; Zdzienicka MZ; Thompson LH; Helleday T; Asada H; Ohnishi T
Biochem Biophys Res Commun; 2011 Jan; 404(1):206-10. PubMed ID: 21111709
[TBL] [Abstract][Full Text] [Related]
15. Different initial steps of apoptosis induced by two types of antineoplastic drugs.
Takagi Y; Hidaka M; Sanada M; Yoshida H; Sekiguchi M
Biochem Pharmacol; 2008 Aug; 76(3):303-11. PubMed ID: 18573489
[TBL] [Abstract][Full Text] [Related]
16. APE1/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line.
Montaldi AP; Godoy PR; Sakamoto-Hojo ET
Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():19-29. PubMed ID: 26520369
[TBL] [Abstract][Full Text] [Related]
17. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT
Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide.
Chai KM; Wang CY; Liaw HJ; Fang KM; Yang CS; Tzeng SF
Oncotarget; 2014 Nov; 5(21):10901-15. PubMed ID: 25337721
[TBL] [Abstract][Full Text] [Related]
19. Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells.
Short SC; Giampieri S; Worku M; Alcaide-German M; Sioftanos G; Bourne S; Lio KI; Shaked-Rabi M; Martindale C
Neuro Oncol; 2011 May; 13(5):487-99. PubMed ID: 21363882
[TBL] [Abstract][Full Text] [Related]
20. FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3.
Wilson JB; Yamamoto K; Marriott AS; Hussain S; Sung P; Hoatlin ME; Mathew CG; Takata M; Thompson LH; Kupfer GM; Jones NJ
Oncogene; 2008 Jun; 27(26):3641-52. PubMed ID: 18212739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
